Marina Neumann
Research Subjects
Research Interests
Marina Neumann has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Leandro Jonata de Carvalho Oliveira
Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), São Paulo, Brazil
1 shared publication - Maria Cecilia Mathias-Machado
Oncoclínicas, Salvador 40050-410, BH, Brazil
1 shared publication - Renata Peixoto
Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
1 shared publication - Victor Hugo Fonseca de Jesus
Medical Oncology Department, A.C. Camargo Cancer Center, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications
Gastrointestinal stromal tumors (GISTs) are malignant mesenchymal tumors arising from the intestinal pacemaker cells of Cajal. They compose a heterogenous group of tumors due to a variety of molecular alterations. The most common gain-of-function mutations in GISTs are either in the KIT (60–70%) or platelet-derived growth factor receptor alpha (PDGFRA) genes (10–15%), which are mutually exclusive. However, a smaller subset, lacking KIT and PDGFRA mutations, is considered wild-type GISTs and presents distinct molecular findings with the activation of different proliferative pathways, structural chromosomal and epigenetic changes, such as inactivation of the NF1 gene, mutations in the succinate dehydrogenase (SDH), BRAF, and RAS genes, and also NTRK fusions. Currently, a molecular evaluation of GISTs is imperative in many scenarios, aiding in treatment decisions from the (neo)adjuvant to the metastatic setting. Here, we review the most recent data on the molecular profile of GISTs and highlight therapeutic implications according to distinct GIST molecular subtypes.
Open AccessCurrent Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications
Gastrointestinal stromal tumors (GISTs) are malignant mesenchymal tumors arising from the intestinal pacemaker cells of Cajal. They compose a heterogenous group of tumors due to a variety of molecular alterations. The most common gain-of-function mutations in GISTs are either in the KIT (60–70%) or platelet-derived growth factor receptor alpha (PDGFRA) genes (10–15%), which are mutually exclusive. However, a smaller subset, lacking KIT and PDGFRA mutations, is considered wild-type GISTs and presents distinct molecular findings with the activation of different proliferative pathways, structural chromosomal and epigenetic changes, such as inactivation of the NF1 gene, mutations in the succinate dehydrogenase (SDH), BRAF, and RAS genes, and also NTRK fusions. Currently, a molecular evaluation of GISTs is imperative in many scenarios, aiding in treatment decisions from the (neo)adjuvant to the metastatic setting. Here, we review the most recent data on the molecular profile of GISTs and highlight therapeutic implications according to distinct GIST molecular subtypes.